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Small Glutamine-Rich 
Tetratricopeptide Repeat-
Containing Protein Alpha (SGTA) 
Ablation Limits Offspring Viability 
and Growth in Mice
Lisa K. Philp1, Tanya K. Day1, Miriam S. Butler1, Geraldine Laven-Law1, Shalini Jindal1, 
Theresa E. Hickey1, Howard I. Scher2, Lisa M. Butler1,3,* & Wayne D. Tilley1,3,*
Small glutamine-rich tetratricopeptide repeat-containing protein α (SGTA) has been implicated as 
a co-chaperone and regulator of androgen and growth hormone receptor (AR, GHR) signalling. We 
investigated the functional consequences of partial and full Sgta ablation in vivo using Cre-lox Sgta-
null mice. Sgta+/− breeders generated viable Sgta−/− offspring, but at less than Mendelian expectancy. 
Sgta−/− breeders were subfertile with small litters and higher neonatal death (P < 0.02). Body size was 
significantly and proportionately smaller in male and female Sgta−/− (vs WT, Sgta+/− P < 0.001) from 
d19. Serum IGF-1 levels were genotype- and sex-dependent. Food intake, muscle and bone mass and 
adiposity were unchanged in Sgta−/−. Vital and sex organs had normal relative weight, morphology 
and histology, although certain androgen-sensitive measures such as penis and preputial size, and 
testis descent, were greater in Sgta−/−. Expression of AR and its targets remained largely unchanged, 
although AR localisation was genotype- and tissue-dependent. Generally expression of other TPR-
containing proteins was unchanged. In conclusion, this thorough investigation of SGTA-null mutation 
reports a mild phenotype of reduced body size. The model’s full potential likely will be realised by 
genetic crosses with other models to interrogate the role of SGTA in the many diseases in which it has 
been implicated.
Small glutamine-rich tetratricopeptide repeat (TPR)-containing protein α (SGTA) belongs to a family of molecu-
lar co-chaperone proteins that possess a TPR motif. This motif, when arrayed in tandem, forms a protein-protein 
interaction module capable of facilitating interactions with a diverse range of client proteins (as reviewed in 
refs 1–3). Since its discovery 15 years ago4, SGTA has been implicated in a myriad of biological processes1 includ-
ing cell cycle and apoptosis5, viral assembly and release4,6–9, hormone signalling5,10–17, intracellular compartmen-
talization10,11, neuronal synaptic transmission18 and the post-translational transport19–22 and modification17,23 of 
proteins. Due to its broad pattern of tissue expression1,24,25 (Suppl Fig. 1A,B) and its engagement in many biolog-
ical processes, SGTA has been implicated in many diseases including cancer of the prostate10,26, ovary27, liver28 
and oesophagus29; hormone-related polycystic ovary syndrome30; and amyloid-related Alzheimer’s18 and prion31 
diseases. Given the overarching cellular role of SGTA in co-chaperoning client proteins to ensure their correct 
folding, trafficking and/or appropriate subcellular movement in the aforementioned biological processes1, it is 
surprising that its essential normal biological functions remain uncharacterised.
Throughout evolution SGTA, and in particular its TPR motif, has remained conserved4,6,10,11,14,32, with ort-
hologs to human Sgta detected in Caenorhabditis elegans32, Drosophila melanogaster33 and Saccharomyces cerevi-
siae32. SGTA is ubiquitously expressed in human and murine tissues, with M. musculus SGTA exhibiting 83% and 
1Adelaide Prostate Cancer Research Centre and Dame Roma Mitchell Cancer Research Laboratories, Faculty of 
Health Sciences, University of Adelaide, Adelaide, Australia. 2Memorial Sloan Kettering Cancer Center, New York, NY, 
USA. 3Freemason’s Foundation Centre for Men’s Health, School of Medicine, Faculty of Health Sciences, University 
of Adelaide, Adelaide, Australia. *These authors contributed equally to this work. Correspondence and requests for 
materials should be addressed to L.K.P. (email: lisa.philp@qut.edu.au) or W.D.T. (email: wayne.tilley@adelaide.edu.au)
Received: 04 January 2016
Accepted: 07 June 2016
Published: 30 June 2016
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 6:28950 | DOI: 10.1038/srep28950
88% identity to human SGTA at the mRNA and protein levels, respectively, with similar distribution of functional 
domains (Suppl Fig. 1D–F). Knockdown of SGTA in vitro can impair cellular proliferation (NBE, HeLa, C4-2B 
cells), reduce cell viability (C4-2B cells)26 and promote cell death (NBE, HeLa cells)5,34. No study to date has 
reported the effect of SGTA ablation in vivo. Given that SGTA is expressed in early development35 and has a ubiq-
uitous co-chaperoning role, we aimed to determine the physiological importance of SGTA in vivo by assessing the 
effect of SGTA ablation on normal development and fecundity in mice.
Results
Sgta−/− Mice are Viable but Tended to Exhibit Reduced Perinatal Viability. Sgta+/− breeders were 
overtly normal in appearance and were fertile, with time to litter comparable to Sgta-intact animals, and viable 
offspring representing all possible genotypes (Sgta−/−, Sgta+/− and WT) were produced (Table 1). Gross pheno-
typic inspection of offspring indicated that all were visibly normal. Sgta+/− breeders yielded litters of normal size, 
with unchanged neonatal mortality rate, as compared to Sgta-intact litters (Table 1). However, the Mendelian 
ratio of inheritance was altered in progeny from Sgta+/− matings; irrespective of gender, Sgta−/− pups tended to be 
less frequently observed than the expected ratio (22.49% vs expected 25%, P = 0.095). However, when separated 
by sex this was most pronounced for female Sgta−/− pups (18.80% vs 25.76% for males, compared to expected 
25%), suggesting that female Sgta−/− mice were less viable during the perinatal period. Sex ratios did not deviate 
from normal (1.06M: 0.94F vs expected 1M: 1F, P = 0.38).
Sgta Knockout was Complete and Global. Having determined that Sgta−/− mice are viable, we next 
characterised the functional consequence of the Sgta disruption. The Cre/Lox knockout strategy used in this 
study (Fig. 1A) involved floxing exons 4 and 5 of M. musculus Sgta for disruption by Cre. In silico analysis of the 
knockout strategy demonstrated that in the case that a stable mRNA species was transcribed, SGTA would be 
truncated at the TPR domain, generating a novel 27 amino acid sequence, followed by a stop codon, theoretically 
producing a 96 amino acid-long protein devoid of TPR-motifs (Fig. 1B). Efficiency of deletion was confirmed by 
PCR (Fig. 1C). At the mRNA level, Sgta abundance was assessed by qRT-PCR using Sgta exon1–3 (‘N-terminal’) 
and Sgta exon4–5 (‘Knockout’) primers in the brain, mammary, ovary, prostate and testis. ‘Knockout’ primers 
failed to amplify product and Sgta knockout mRNA levels were dose-dependent for Sgta WT, +/− and −/− tissues 
(P < 0.001; Fig. 1D). Homozygous Sgta-null mice exhibited severely blunted Sgta ‘N-terminal’ mRNA expression. 
Again, ‘N-terminal’ Sgta mRNA levels were dose-dependent (P < 0.001; Fig. 1D). These data demonstrate that 
this strategy resulted in mice completely lacking Sgta mRNA, rather than a functional knockout. Complete abla-
tion of SGTA protein was confirmed by Western blot analyses (Fig. 1E), but was apparent in a dose-dependent 
manner in WT and Sgta+/− as expected. In the event that a truncated protein was translated following deletion of 
Sgta exon4–5, its predicted weight would be ~10.6 kDa. Even when protein was subjected to gel electrophoresis 
using high percentage gels specially designed to enable separation of low molecular weight proteins (as low as 
2kDa), no ~10kDa bands were detected (data not shown). The complete lack of SGTA protein was confirmed by 
immunohistochemistry in prostate and ovary (Fig. 1E) using an antibody raised against ‘N-terminal’ SGTA. We 
therefore conclude that ablation of SGTA protein in these mice was both global and complete.
Full, but not Partial, Sgta Deficiency Elicits a Phenotype of Reduced Body Size. From weaning 
through to adulthood (20–60 wks), and irrespective of gender, Sgta−/− mice weighed significantly less than their 
Sgta+/− and WT littermates (P < 0.001; Fig. 2A). Body length was reduced in Sgta−/− adult males and females as 
compared to Sgta+/− and WT littermates (P < 0.001), confirming that Sgta−/− mice were proportionately smaller 
(Fig. 2B). Reduced adiposity did not contribute to lower body mass in Sgta−/− adults, as neither the absolute nor 
relative mass of 4 pooled adipose tissue depots were affected by genotype (Fig. 2B). Adipose tissue cellularity was 
also unaffected at the microscopic level, as assessed by a pathologist (Suppl Fig. 2). Changes in lean and skeletal mass 
are logical contributors for this size difference. However, pooled absolute hind limb muscle mass, whilst signifi-
cantly reduced in Sgta−/− adult mice vs Sgta+/− and WT (P < 0.01), was unchanged when expressed relative to body 
Breeder Statistics Sgta−/− x Sgta−/− Sgta+/− x Sgta+/− Intact Comparator
Number of Breeding Pairs 6 15 6
Number of Litters 18 40 13
Average Litter Size (± SEM) 6.11 ( ± 0.58)†‡ 7.33 ( ± 0.41) 7.54 ( ± 0.70)
Average Days to Litter (± SEM) 30.14 ( ± 3.54) 27.56 ( ± 2.18) 25.83 ( ± 2.75)
Offspring Statistics Sgta−/− x Sgta−/− Sgta+/− x Sgta+/− Intact Comparator
Total Pups Born 110 293 98
Live Pups Born 104 (94.55%) 288 (98.29%) 96 (97.96%)
Stillborn Pups 6 (5.45%) 5 (1.71%) 2 (2.04%)
Neonatal Deaths 32 (30.77%)* # 39 (11.46%) 9 (9.38%)
Pups Weaned 72 (69.23%)* # 249 (86.46%) 87 (90.63%)
Male Pups Weaned 34 (47.22%) 132 (53.01%) 50 (57.47%)
Female Pups Weaned 38 (52.78%) 117 (46.99%) 37 (42.53%)
Table 1.  Reproductive Demographics of Heterozygous and Homozygous Sgta-deficient Breeding Pairs. 
Statistics: #P ≤ 0.05, trend †P < 0.10, vs intact; * P ≤ 0.01, trend ‡P < 0.06, vs Sgta+/−.
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Figure 1. Generation of Mice Null for Small Glutamine-rich Tetratricopeptide Repeat-containing Protein 
Alpha (SGTA). (A) Genomic structure of the mouse Sgta gene floxed at exons 4 and 5, and schematic of the 
resultant knockout product. (B) Protein sequence of wild-type SGTA, with TPR1, 2 and 3 highlighted in blue, 
red and green, respectively, and effect of exons 4–5 (amino acids 271–458) deletion leading to a 96 amino acid 
product. (C) PCR analyses confirming Sgta deletion in heterozygous (+ /− ) and homozygous (− /− ) Sgta-null 
mice using ‘SGTA knockout’ primers, and the presence of Sgta in wild-type (WT) and Sgta heterozygous  
(+ /− ) mice, using ‘SGTA intact’ primers and finally the removal of Cre Recombinase (Cre) in a subset of 
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weight (Fig. 2B). Skeletal muscle was also histologically normal across genotypes (Suppl Fig. 2). Likewise, absolute 
femur weight, whilst significantly reduced in Sgta−/− vs WT adults (P < 0.03), when corrected for body weight, was 
unchanged (Fig. 2B). Therefore changes in lean and skeletal mass are unlikely to account for smaller body mass.
We next aimed to determine the timing and cause of body weight divergence as a result of Sgta ablation. 
Sgta-null neonates appeared macroscopically indistinguishable from WT, displaying no signs of disadvantage 
(Fig. 2C). Measuring pup weight from birth to weaning (Fig. 2C) revealed a genotype* age interaction (P < 0.02). 
From postnatal d0-7, Sgta−/− pups exhibited similar body weight to Sgta+/− and WT littermates. While body 
weights were monitored from birth, it was not until day 19 onwards that Sgta−/− pup weight diverged significantly 
from Sgta+/− and WT animals (P < 0.02; Fig. 2C inset). Feed intake did not account for smaller body mass as feed 
efficiency, measured from postnatal d21-105 was unchanged by genotype (Fig. 3A) and during early neonatal life, 
milk bands were clearly visible (Fig. 2C inset).
Effects of Sgta Ablation on Endocrine Growth Mediators. Serum growth hormone (GH) levels were 
highly variable and did not significantly differ by genotype (Fig. 3B), but serum levels of another growth mediator, 
IGF-136, were genotype- and sex-dependent (Genotype* Sex: P < 0.01). In males, serum IGF-1 levels were lower in 
Sgta−/− than Sgta+/− and WT (P < 0.01; Fig. 3B). In females, serum IGF-1 was lower in Sgta+/− (P < 0.02), but not 
Sgta−/− mice, compared to WT (Fig. 3B). mRNA expression of the receptors responsible for GH and IGF-1 action, 
growth hormone receptor (Ghr) and Igf-1 receptor (Igf-1r), and for Igf-1 transcript were assessed by qRT-PCR 
in tissues. In the ovary, Ghr mRNA was higher in Sgta−/− than WT (P < 0.03), but levels were unchanged by gen-
otype in the mammary, prostate or testis (Table 2). Igf-1 mRNA levels were significantly lower in the mammary 
gland of Sgta−/− females than Sgta+/− (P < 0.05; Table 2). In testis, Igf-1 mRNA was unchanged with genotype, as 
were Igf-1r mRNA levels in the ovary, mammary, prostate and testis (Table 2).
Sgta−/− Breeders Bear Offspring with Reduced Perinatal Viability. As Sgta-null mice were via-
ble, male and female Sgta−/− mice were paired to assess fecundity. Subfertility and reduced pup viability were 
observed in this cohort (Table 1). Litter size trended smaller when from Sgta−/− breeding pairs, vs litters from 
Sgta+/− (P < 0.06) breeders. Delayed time to litter with decreasing Sgta ‘dose’ (Sgta-WT > Sgta+/− > Sgta−/−) failed 
to reach significance (P = 0.17). Offspring were no more susceptible to stillbirth, but were more prone to neonatal 
death between postnatal d2-21 and markedly less mice survived to weaning in Sgta−/− vs Sgta-intact (P < 0.02) 
and Sgta+/− (P < 0.01). Sex ratios in Sgta−/− litters did not deviate from normal (0.94M:1.06F vs expected 1:1, 
P = 0.72).
Effect of Sgta Ablation on Reproductive Organ Development and AR Signalling. SGTA has been 
implicated as a putative co-chaperone for the AR and is believed to limit translocation of AR to the nucleus until 
the AR complex is ligand-bound10. Androgen and AR signalling pathways are involved in the development of the 
male-specific phenotype during early development and in spermatogenesis, sexual behaviour and fertility in male 
adult life, but are also important in female sex organ development, including uterus and breast, and normal repro-
ductive physiology, such as ovarian folliculogenesis and embryonic implantation, in females. Chemical or genetic 
disruption of androgen/AR signalling perturbs normal male and female reproductive development or func-
tion37,38. We therefore assessed AGD (testis descent) and penis and preputial size as surrogates for androgen/AR 
signalling during early prenatal, prepubertal37,38 and pubertal39,40 development, respectively (Fig. 4A,B).
In general, the phenotypic effects of SGTA deficiency on the male reproductive system were subtle. The 
most significant effect was on testis descent, as AGD was significantly increased in Sgta−/− males compared to 
other males (WT and Sgta+/−; P < 0.001; Fig. 4A). Penis length was increased in Sgta−/− vs WT males (P < 0.02; 
Fig. 4A), and penis weight was greater in Sgta+/− (P < 0.05), and trended higher in Sgta−/− (P = 0.062), vs WT 
(Fig. 4B). Similarly, preputial gland weight was greater in Sgta+/− vs WT males (P < 0.05; Fig. 4B). However, other 
male reproductive organs were unchanged as a result of homozygous Sgta ablation in their mass (Suppl Fig. 3A), 
macroscopic appearance (Suppl Fig. 3B) and pathology (Suppl Fig. 2) when compared to WT. Sgta−/− males also 
exhibited sperm in both the testes, the site of spermatogenesis41, and epididymis, the site of sperm maturation and 
storage42. Similarly, female reproductive organs were unchanged as a result of homozygous Sgta ablation in their 
mass (Suppl Fig. 3C), morphology (Suppl Fig. 3D) or histology (Suppl Fig. 2) when compared to WT. The ovaries, 
which depend on androgens for normal function and early follicular development38, were phenotypically normal 
at the macro- (Suppl Fig. 3C), and microscopic levels in Sgta−/− females as assessed by a pathologist (Suppl Fig. 2). 
Ovaries also exhibited follicles at all stages of follicular development43, including primordial, primary, secondary 
and antral follicles, and the corpus luteum.
Sgta+/− mice (L, ladder; bp, base pairs; H2O, water control; M, male; F, female; N.B. ladder’s two brightest bands 
at 1000 (upper) and 500 (lower) bp). (D) Quantitative Real Time PCR confirming homozygous Sgta mutation 
ablated Sgta mRNA compared to Sgta+/− and WT, while heterozygous Sgta mutation significantly diminished 
Sgta mRNA compared to WT. Analyses were conducted in brain, mammary, ovary, prostate, and testis tissues 
with primers spanning in either Sgta exon 1–3 and Sgta exon 4–5. Means (n = 8/group) with different letters 
are significantly different, P < 0.001. (E) Western blots (brain) and immunohistochemistry (prostate, ovary) 
confirming loss of SGTA protein in homozygous Sgta-null (− /− ) tissue and lowered SGTA protein expression 
in heterozygous Sgta-null (+ /− ) tissue (LC, loading control; N-SGTA, probed with ‘N-terminal’ SGTA 
antibody; F-SGTA, probed with ‘Full length’ SGTA antibody; H-3, Histone H-3; ACT, Actin). For Western blots, 
representative cropped blots are depicted, with all blots run under the same experimental conditions. Scale bars 
represent 50μ m.
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As some, but not all, androgen-regulated organs displayed potential signs of hyperandrogenisation during 
development in Sgta+/− and Sgta−/− mutants, we measured Ar mRNA expression in androgen-regulated tissues, 
the brain, and the prostate and testis in males, and the mammary and ovary in females (Fig. 4C). Ar mRNA was 
unchanged by genotype in the prostate, testis, ovary, mammary and brain. To determine if Sgta ablation altered 
the localisation and distribution of AR protein, we undertook dual-labelled immunofluorescence staining of 
prostate and testis sections (Fig. 4D). In the prostate, SGTA protein resided chiefly in the cytoplasm of WT and 
Sgta+/− epithelial cells, with weaker intensity staining in Sgta+/− than WT, and no staining in Sgta−/− animals, as 
expected (Fig. 4D). Conversely, AR protein was principally nuclear in WT and Sgta+/− prostate epithelial cells, 
with weaker intensity staining in Sgta+/− vs WT. However, in Sgta−/− prostates, AR immunostaining was equally 
as intense as in the nuclei of WT prostate, but exhibited greater immunoreactivity in the cytoplasm than WT and 
Sgta+/−. In the testis, SGTA was also localised predominantly in the cytoplasm of cells and was detected in the 
Leydig, Sertoli, spermatid and spermatocyte cells of WT testis (Fig. 4D). AR immunostaining was detected pre-
dominantly within the Leydig cells, with intense nuclear and distinct cytoplasmic immunoreactivity in WT testis. 
Partial Sgta ablation increased AR immunoreactivity, especially in the cytoplasm of Leydig cells, although distinct 
nuclear immunostaining was also detected. And finally, full Sgta ablation was associated with a visual reduction 
Figure 2. Morphological Analysis of Sgta-deficient Male and Female Mice at Adult and Neonatal Time 
Points. (A) Body weight growth curves from weaning to adulthood (n = males (M), WT = 23–32, + /− = 45–57, 
− /− = 19–24; females (F), WT = 24–34, + /− = 36–49; − /− = 10–14) and representative images of adult male 
and female WT, Sgta+/− and Sgta−/− mice. (B) Adult body length (n = 8–15/group) and the mass of pooled 
adipose tissue (AT) (n = 7–10/group), hind limb skeletal muscles (n = 7–10/group) and the femur (n = 6–9/
group) relative to body weight. (C) Body weight growth curves from birth to weaning (n = M, F WT = 8, 6,  
+ /− = 8, 8 − /− = 9, 5) and representative images of neonatal male and female WT, Sgta+/− and Sgta−/− mice. 
(A–D) Statistics: N.B. G, genotype; A, age, S, sex, * denotes an interaction. Means with different letters are 
significantly different, P < 0.05.
www.nature.com/scientificreports/
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of AR immunoreactivity, especially in the cytoplasm, although some nuclear and cytoplasmic staining was still 
observed (Fig. 4D). Hence, some tissue-specific effects of SGTA dosage were evident. In order to determine if 
these changes were associated with changes in AR signalling, the mRNA content of known androgen-regulated 
target genes was assessed in the testis, prostate, ovary and mammary (Table 2). None of the AR-dependent genes 
measured were altered as a result of full or partial Sgta ablation.
Relative to Body Weight, Organs Weights were Mostly Unchanged, Pathology was Normal and 
Aging was Associated with no Genotype-specific Abnormalities. As the majority of organs tended to 
exhibit lighter absolute weight in Sgta−/−, presumably due to their smaller body size, we assessed the effect of geno-
type on organ weights relative to body weight. This allowed direct comparison between genotype and gender. Other 
than an increased heart weight in Sgta+/− vs WT (P < 0.05), brain weight in Sgta−/− vs WT (P < 0.02), and intestine 
weight in Sgta−/− than WT (P < 0.11), and a reduced relative stomach weight in Sgta+/− vs Sgta−/− (P < 0.02) and 
WT (P < 0.06), the mass of most vital organs relative to body weight was unchanged by genotype (Suppl Fig. 3E,F). 
All organs were also phenotypically normal in terms of morphology and pathology (Suppl Fig. 2).
Aging is considered to be a stressor and is associated with the accumulation of misfolded proteins44. Given the 
key role of SGTA in protein processing and folding1, we were interested to determine if aging resulted in a more 
Gene
Males Females
Tissue WT Sgta+/− Sgta−/− Tissue WT Sgta+/− Sgta−/−
Growth Mediators
Ghr PRO 12.02 ± 0.98 10.21 ± 1.22 9.34 ± 1.32 MAM 4.44 ± 0.64 5.15 ± 0.57 4.93 ± 0.63
Ghr TES 0.05 ± 0.004 0.05 ± 0.001 0.05 ± 0.002 OVA 2.42 ± 0.19a 3.16 ± 0.20ab 3.42 ± 0.33b
Igf-1 PRO 1.28  ± 0.11 1.16 ± 0.10 0.96 ± 0.09 MAM 3.84 ± 0.38ab 5.21 ± 0.62a 3.25 ± 0.60b
Igf-1 TES 0.28  ± 0.03 0.28 ± 0.02 0.28 ± 0.02 OVA 2.24  ± 0.17 2.54 ± 0.15 2.77 ± 0.16
Igf-1r PRO 11.46 ± 0.81 11.67 ± 0.92 10.53 ± 0.86 MAM 4.22 ± 0.42 4.29 ± 0.19 4.63 ± 0.48
Igf-1r TES 0.87 ± 0.07 0.77 ± 0.04 0.89 ± 0.05 OVA 3.56 ± 0.25 3.72 ± 0.22 3.68 ± 0.18
Androgen-Regulated
Hp-1 PRO 0.07 ± 0.03 0.05 ± 0.02 0.02 ± 0.02 MAM 2.56 ± 0.31 3.39 ± 0.32 3.48 ± 0.56
Hp-1 OVA 0.39 ± 0.03 0.41 ± 0.03 0.42 ± 0.03
Odc1 PRO 0.35 ± 0.03 0.38 ± 0.03 0.34 ± 0.03 MAM 0.16 ± 0.01 0.17 ± 0.01 0.17 ± 0.01
Odc1 TES 0.93 ± 0.05 0.90 ± 0.04 0.94 ± 0.06 OVA 0.39 ± 0.03 0.41 ± 0.03 0.42 ± 0.03
Rhox5 TES 0.84 ± 0.05 0.77 ± 0.04 0.94 ± 0.09 OVA 0.89 ± 0.13 1.00 ± 0.15 1.04 ± 0.21
Table 2.  Growth Mediator and Androgen-Regulated mRNA Expression in the Prostate (PRO), Testis 
(TES), Mammary (MAM) and Ovary (OVA) Tissue of Adult Sgta-null Mice. Means with different letters are 
significantly different, P < 0.05.
Figure 3. Analysis of Growth Mediators in Adult Sgta-deficient Male and Female Mice. (A) Feed efficiency 
(n = M, F WT = 8, 6 + /− = 8, 8 − /− = 9, 5). (B) Serum concentrations (n = 6/group) of growth hormone 
(GH) and insulin-like growth factor 1 (IGF-1). (A,B) Statistics: N.B. G, genotype; A, age, S, sex, * denotes an 
interaction. Means with different letters are significantly different, P < 0.05.
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pronounced phenotype in Sgta-null animals. However, the relative weights of vital and sex organs, adipose tissue, 
muscle and bone were not affected by a genotype* age interaction, suggesting that Sgta-null mice are not any more 
vulnerable to age-related stress than WT. SGTA has also been implicated in neuro-synaptic transmission13 and in 
responses to amyloid-associated toxicity18, however in this study Sgta-null animals showed no overt symptoms of 
neurodegeneration in either adulthood or aging.
Other TPR-Containing Proteins are Largely Unchanged in Sgta−/− Mice. Given the mild pheno-
type observed in Sgta−/− animals, we hypothesised that one or multiple TPR-containing proteins1 could possibly 
Figure 4. The Effect of Full and Partial SGTA Deficiency on Androgen-Regulated Measures and AR 
Signalling. (A) Androgen-regulated developmental measures including anogenital distance (AGD; n = 12–15/
group, bar Sgta−/− F, n = 7) and penis length in WT, Sgta+/− and Sgta−/− adult mice. (B) Androgen-regulated 
developmental measures including penis and preputial gland weight (n = 7–9/group) in WT, Sgta+/− and 
Sgta−/− adult mice. (C) Ar mRNA expression in the brain, mammary, ovary, prostate and testis of WT, Sgta+/− 
and Sgta−/− adult mice (n = 7–8/group). (D) Representative images of AR (green) and SGTA (red) protein co-
localisation in the prostate and testis of WT, Sgta+/− and Sgta−/− adult mice. Statistics: N.B. G, genotype; S, sex. 
Means with different letters are significantly different, P < 0.05.
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fulfil the cellular role of SGTA and prevent catastrophic dysfunction in co-chaperone assisted pathways (Fig. 5). 
However, in the brain (Fig. 5A), prostate (Fig. 5B) and testis (Fig. 5C), ovary and mammary, expression of Stub1, 
Sgtb, Ppp5c, Ppid, Fkbp4, Fkbp5 mRNAs were not affected by genotype. However, Dnajc7 was increased in Sgta−/− 
ovary compared to WT and Sgta+/− (P < 0.01, P < 0.03, respectively; Fig. 5E).
Discussion
Recent studies from our laboratory10,26,27 and others28,29, have linked altered SGTA expression to tumour cell pro-
liferation and/or cancer prognosis. This is not surprising, given that SGTA has been implicated in cell cycle and 
apoptosis5,45,46 and in the molecular co-chaperoning of numerous protein clients to ensure their correct folding, 
compartmentalisation and/or trafficking1. Each of these processes, if defective, has the potential to contribute to 
tumorigenesis. Aside from a role in the pathophysiology of several disease-states10,18,26–31, little is known about the 
normal physiological role of SGTA.
In vitro, SGTA knockdown in kidney (NBE)34, cervical cancer (HeLa)5 and prostate cancer (C4-2B)26 cells 
reduces proliferation and viability due to impaired mitosis5,34, in association with defective cytokinesis34 and 
failed completion of chromosomal alignment5. Because of this, and the fact that Sgta is ubiquitously expressed 
and a wide range of protein interactions with SGTA are documented1, we hypothesised that Sgta would be vital 
for life and that its ablation in mice would prove lethal. On the contrary, however, we demonstrated here that 
viable Sgta−/− animals were produced from breeding Sgta-deficient mice, as is the case in the knockout/down of 
conserved SGTA orthologs32,33 in C. elegans, D. melanogaster and S. cerevisiae14,15,33. The tendency we observed 
for reduced numbers of Sgta−/− offspring in comparison to expected Mendelian inheritance is consistent with 
that of mutants for similar TPR-containing protein, FKBP52 (Fkbp4)47,48. Given considerable evidence that SGTA 
is involved in tail-anchored (TA) protein insertion16,22,49, and as TA biogenesis is essential for early development 
and genetic ablation disrupting this process has been linked to embryonic lethality50,51, it is possible that aberrant 
TA protein processing may contribute to the reduced yield of mutant animals. The cause of prenatal mortality 
remains undetermined, however, in the case of FKBP52−/−, genetic background did contribute to the penetrance 
Figure 5. TPR-containing Protein mRNA Expression Levels in the Brain, Prostate, Testis, Mammary and 
Ovary of WT, Sgta+/− and Sgta−/− Adult Mice. TPR-containing proteins in the (A) brain, (B) prostate,  
(C) testis, (D) mammary and (E) ovary. TPR-containing proteins measured were tetratricopeptide repeat 
protein 2 (TPR2/Dnajc7), peptidyl-prolyl cis-trans isomerase FKBP4 (FKBP52/Fkbp4), peptidyl-prolyl cis-trans 
isomerase FKBP5 (FKBP51/Fkbp5), cyclophilin 40 (CYP40/Ppid), protein phosphatase 5 (PP5/Ppp5c), small 
glutamine-rich tetratricopeptide repeat-containing protein beta (SGTB/Sgtb) and carboxy terminus of Hsp70-
interacting protein (CHIP/Stub1) (n = 7–9/group). Statistics: Means with different letters are significantly 
different, P < 0.05.
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of FKBP52 action. That is, independent generation of FKBP52−/− mice on C57BL/6J47 and 129SvEv48 back-
grounds yielded lethality at 50% and 30% of embryos from heterozygous matings, respectively. Moreover, back-
crossing FKBP52-129SvEv mutants to the C57BL/6 strain amplified lethality to almost 100%52; highlighting the 
caveat that the underlying genetics of a mutant model influence the phenotype presented. Whether a more pro-
nounced phenotype of Sgta−/− would have been observed if it been characterised on a different background strain 
of mice, remains to be determined. In contrast to FKBP52−/−, deletion of the similar protein, FKBP51 (Fkbp5), 
had no effect on early survival and elicited no apparent altered phenotype in mice53, although FKBP51 knockout 
(C57BL/6J background) in combination with FKPB52 deletion (129SvEv background) caused complete lethality 
in early embryonic life54. This highlights that redundancy exists in the co-chaperoning system. Consistent with 
this notion, FKBP52−/− males developed normal testes, but displayed penile hypospadias53. Increased FKBP51 
mRNA and protein expression in FKBP52−/− testis, but not in penis, may actively prevent testis dysgenesis. In 
the context of homozygous Sgta ablation, it is possible that a structurally similar TPR-containing protein(s) inter-
venes, fulfilling the role of SGTA in its absence. Increased Dnajc7 (TPR2) mRNA in the ovary may serve this 
purpose, however the mRNA expression of 7 TPR-containing proteins was unchanged in the prostate, testis and 
mammary gland. Whether changes in protein expression and/or localisation of TPR-containing protein(s) com-
pensate for loss of SGTA in normal physiology merits further investigation and could explain why only a mild 
Sgta-null phenotype was observed in the current study. A more overt phenotype may be induced by applying 
a stressor to Sgta-null mutants, as co-chaperones are essential for optimal folding/refolding and trafficking of 
stress-affected client proteins55. In yeast null for SGTA ortholog, Sgt-2, two distinct cellular stressors reduced 
yeast viability15, growth and colony formation20 compared to wild-type yeast. This further supports that SGTA is 
essential under certain cellular conditions and it is likely that its loss is compensated for to prevent dysfunction 
when these conditions arise.
In Sgta-null mice, reduced body size comprising a proportionate decrease in body weight and length was the 
most overt phenotypic change observed and was limited to homozygous mutants. Inadequate nutrition could 
result in stunted Sgta−/− growth, especially as weight differences coincided with a phase where dependence on 
nursing is lessened. This appears not to be the case, as feed efficiency was unchanged in Sgta−/− mice, albeit their 
ability to absorb and utilise nutrients from food consumed remains unknown. Whether Sgta ablation prompted 
changes in the signalling of hormonal growth mediators warranted investigation, especially as myostatin23 and 
the GHR12 are SGTA client proteins. Defective development and altered mass of skeletal muscle would be pre-
dicted if Sgta deficiency influenced the maturation and signalling of myostatin, a negative regulator of muscle 
mass56; however neither muscle pathology nor mass were affected. GH, acting via GHR, is essential for somatic 
growth, cellular differentiation57, and paracrine production of IGF-1 36. Aberrant GHR signalling, and GH resist-
ance, causes cessation of IGF-1 production and growth stunting. Despite both GH and GHR normally being 
expressed in early embryogenesis, growth changes due to altered GH signalling are only observed from postnatal 
d14-21 in mice36,58. Dwarfing at 3 weeks in GHR-null mice is associated with heightened GH and lowered levels 
of IGF-1 in the circulation36,58. Likewise, decreasing functional IGF-1R in mice (IGF-1Rneo) leads to growth 
stunting from 4–9 weeks of age, corresponding to a plateau in size, which is maintained59. Analogous to GHR/
IGF-1R deficiency58,59, Sgta-null mutants emerged as being physically smaller than WT at ~3 weeks and plateaued 
at ~6 weeks, at which time females were 93%, and males 87%, of the weight of WT animals. Similar to GH/GHR, 
SGTA is detected prenatally in the embryo, but its functionality during early development is not known. Given 
its interaction with the ubiquitin-dependent endocytosis motif of precursor and mature GHR, SGTA has been 
speculated to prevent GHR interaction with ubiquitin machinery whilst being trafficked from the endoplasmic 
reticulum, where precursor GHR resides, to the cell membrane, where mature GHR functions57. Aberrant GHR/
IGF-1R trafficking and potentially ubiquitin-mediated GHR degradation could be triggered by Sgta ablation. We 
hypothesise that this may contribute to the growth stunting observed in Sgta−/− mice, providing the loss of SGTA 
is not compensated by another co-chaperone. Lowered IGF-1 serum and tissue mRNA levels in Sgta−/− animals 
may reflect defective GHR signalling, whereas raised serum GH and elevated GHR in the ovary in Sgta−/− may 
indicate compensation for deficient GH/IGF-1 signalling; however, the latter requires confirmation at the protein 
level.
Unlike homozygous FKBP52 deletion which rendered mice sterile53, Sgta deficiency elicited only mild 
subfertility in this study. Dysgenesis in sex organs dependent on androgen/AR-driven development were the 
leading cause of defective FKBP52−/− male reproduction53, while failure of progesterone receptor-dependent 
uterine implantation conferred sterility in FKBP52−/− females48. Increased surrogate measures (AGD, penis 
and preputial gland size) for androgen signalling in utero, both prepubertally and at puberty, in full or partial 
Sgta deficiency are suggestive of altered AR signalling and/or hyperandrogenisation. However, several other 
androgen-dependent organs were unaffected by Sgta ablation in males and females, as was the mRNA expres-
sion of Ar and AR-responsive genes. Regardless, an effect of Sgta ablation on sex steroid production cannot be 
excluded. In addition to AR regulation, SGTA also exhibits regulatory specificity for progesterone and gluco-
corticoid receptors1,60; thus the influence of SGTA ablation on biological processes controlled by progesterone 
and glucocorticoid signaling also warrant future investigation. Reduced nuclear AR immunoreactivity without 
a concomitant increase in the cytoplasm in the Sgta+/− prostate, is suggestive of Sgta, like other TPR-containing 
proteins TPR2/Dnajc7 and CHIP/Stub1, playing a role in AR stabilisation and/or degradation61. This appears to 
be the case for GHR12, where its stabilisation is not compensated for in an environment of partial Sgta deficiency.
In summary, this study has provided an intriguing first glimpse into the multi-faceted role of SGTA in vivo. 
Full, but not partial, ablation of SGTA conferred subfertility and limited the viability and growth of offspring. The 
complex interplay of molecular co-chaperones and the importance of redundancy in their physiological roles, 
particularly in hormone receptor maturation and signalling, is highlighted by the current findings. This Sgta-null 
model is amenable to further study of several clinical disorders, including hormone-dependent and β -amyloid 
diseases, where a role for SGTA has been implicated.
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Materials and Methods
Ethics Statement. All procedures were approved by the University of Adelaide Animal Ethics Committee 
(M-2012-028, M-2014-050 and M-2010-016) and all studies were conducted in accordance with accepted stand-
ards of humane animal care, as outlined in the Australian Code of Practice for the Care and Use of Animals for 
Scientific Purposes, and within University of Adelaide guidelines for the use and care of laboratory animals.
Generation and Maintenance of Sgta-Null Mice. Heterozygous Sgta knockout mice were generated 
by Ozgene Pty Ltd (Bentley, Aus.). The gene encoding M. musculus Sgta is located on Chromosome 10 and has 
12 exons, 10 of which are protein coding. Structurally, SGTA exhibits a central tandem array of 3 TPR motifs, a 
glutamine-rich C-terminal domain and an N-terminal domain containing a potential short coiled coil motif (as 
reviewed in1). Our strategy was to delete the coding region of exons 4 and 5 of M. musculus Sgta. This approach 
would result in either: (1) cryptic splicing between exons 3–6, generating a stable mRNA coding for a truncated 
protein lacking the key functional domains, TPR1 and TPR2, for a functional knockout, or (2) a transcript lacking 
exons 4 and 5, potentially rendering it unstable and leading to a complete knockout.
A targeting vector was designed to introduce a conditional mutation into the mouse Sgta gene (Ensembl gene 
ID: ENSMUSG00000004937; NCBI Nucleotide Accession number: NM_024499) (Suppl Fig. 1C), employing 
mutant loxP sites to enable deletion of the loxP flanked (“floxed”) sequence under Cre recombinase-expressing 
conditions. LoxP sites were inserted into the introns flanking exons 4 and 5, incorporating TPR1 completely and 
part of TPR2 of M. musculus Sgta. The loxP site flanking exon 4 was inserted upstream and the loxP site flanking 
exon 5 was inserted downstream of a neomycin selection cassette (Phosphoglycerate Kinase (PGK)-neo). The 
selection cassette was flanked with Flippase Recognition Target (FRT) sites to enable removal by FLPe-mediated 
recombination. The targeting vector was inserted into a plasmid backbone PelleR (Ozgene) containing the 
PGK-neo cassette (Suppl Fig. 1C), linearised and electroporated into C57BL/6-derived embryonic stem cells 
(Ozgene). Correctly targeted stem cell clones were microinjected into recipient murine blastocysts, which were 
transferred into pseudo-pregnant foster mothers. Offspring were crossed with C57BL/6 mice to generate embry-
onic stem cell-derived targeted mutant progeny (heterozygous Sgta wt/flox), as confirmed by genotyping. These 
mice were crossed with OzCre mice, which express Cre knocked into the ubiquitously expressed Gt(ROSA)26Sor 
locus. Global tissue expression of Cre initiated loxP-mediated deletion of exons 4 and 5 of Sgta in early embryonic 
development and generation of Sgta+/− + Cre mice. To minimise the impact of Cre-related toxicity62, Cre was 
eradicated by back-crossing Sgta+/− Cre mice to C57BL/6 and it was only Cre-negative (Δ Cre) mice that were 
used subsequently and described herein.
Mice were housed under specific pathogen-free conditions on a 12-hr light/dark cycle at the University of 
Adelaide Medical School Animal House (Adelaide, Aus). Mice were group-housed (unless specified below) in 
individually ventilated cages in a temperature-controlled environment and were provided autoclaved standard 
rodent chow (Meat Free Rat and Mouse Diet, Specialty Feeds, Glen Forrest, Aus; 14.0 mJ/kg (23% and 12% energy 
from protein and fat, respectively, pre-autoclave)) and water ad libitum.
PCR-based Genotyping. Confirmation of removal of the “floxed” Sgta sequence in mice was determined 
by PCR-based genotyping. Extraction of genomic DNA from tail or ear clippings was performed using the 
REDExtract-N-Amp Tissue PCR Kit (Sigma-Aldrich, St Louis, US) according to manufacturer’s instructions. A 
portion of this DNA was applied to PCR-based genotyping for the determination of the presence of (1) Sgta alleles 
(WT vs knockout) and (2) Cre (positive or negative).
(1) Genotyping for the Sgta alleles employed 2 primer sets, referred to as ‘SGTA Knockout’ or ‘SGTA Intact’ 
primer pairs. The ‘SGTA Knockout’ primer pair was designed to yield a 389 bp product in response to a 
deleted Sgta allele (+ /− , − /− ) and a higher molecular weight product (450 bp) was observed in the pres-
ence of WT Sgta alleles. The ‘SGTA Intact’ primer pair was designed to yield a 765 bp product in response 
to an intact Sgta allele (WT, + /− ) and the absence of a product in the presence of homozygous Sgta dele-
tion (− /− ). Genotyping primer sequences (5′ -3′ ) were as follows, ‘SGTA Knockout’: Forward (FWD) 
CACAGTTGCCATCCAGTGTC and Reverse (REV) CTGGGGAGAGGAAACTGTCAGT; ‘SGTA Intact’: 
FWD TGACAGGACACCACCCTCTGAA and REV GGAGGGTCAGCCTGGGTTAAA.
(2) Genotyping reactions for identifying the presence of Cre utilised a published primer pair63 that yields a 727 bp 
product in the presence of Cre and no product in its absence.
PCR conditions were an initial denaturation at 94 °C for 3 min; 34 cycles of 92 °C for 1 min, 58 °C for 1 min and 
72 °C for 2 min; followed by final elongation at 72 °C for 10 min.
SGTA mRNA in Normal Human Tissues and Gene Expression during Development in Mice. The 
distribution of SGTA mRNA in normal human tissue samples was assessed from publically available data through 
the Oncomine database (https://www.oncomine.org/). SGTA mRNA content (log2 median-centred intensity) 
was measured using the Human Genome U133 Plus 2.0 Array on 504 and 353 normal human tissue samples for 
the Roth Normal and Roth Normal 2 cohorts, respectively35. A heat map was generated using conditional for-
matting and a colour scale based on the value in the cell and represented graphically, and categorised into tissues 
of endodermal, ectodermal and mesodermal embryonic origin (Suppl Fig. 1A). Mouse Sgta gene expression 
during embryonic development and in gametes was assessed using public data in Gene Expression Barcode 3.0 
(http://barcode.luhs.org/).
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Assessment of Fertility, Breeding Efficiency and Offspring Viability. All Sgta+/− and Sgta−/− breed-
ing pairs were monitored for time to litter (date paired to date litter born) and pup yield was assessed for litter 
size, live born, stillborn (birth/d1) and neonatal death (postnatal d2-21). Offspring were reared by their mother 
until 3 wks-of-age, at which point they were removed from the breeding cage, weaned, sexed, tail-tipped (for 
genotyping), and placed in a cage with littermates of the same sex. Genotype distribution of litters was monitored 
for normal Mendelian inheritance in the case of Sgta+/− breeders. Sex distributions were determined for all litters. 
From 3 wks, body weight was determined once-weekly.
Birth Weight, Pup Body Weight and Food Intake. A cohort of offspring from Sgta+/− and Sgta−/− 
breeders were analysed for birth weight (d0), neonatal weight (d1-21) and for food intake or for body weight 
post-weaning (d21-105). To assess birth weight, a cohort of female breeders were left paired with males and 
checked daily 1–5 hrs after lights-on (7 AM), and any newborn pups were weighed. Pups were weighed daily 
and any dead pups collected and genotyped for SGTA status and sex. Upon weaning (strictly at d21), pups were 
individually housed and food intake assessed. During food intake assessment, food and water were provided 
ad libitum. From d 21-105, feed was first weighed, then placed in the cage for ~24 hrs whereupon the remaining 
feed and crumbs were weighed. Feed efficiency was calculated as weight gained from d21-105, relative to cumu-
lative feed consumption for this time period (g weight gained/g feed consumed* 100).
Post-mortem Tissue Collection. A cohort of offspring from Sgta+/− breeding pairs were assessed for 
phenotypic differences at adult (20 wks-of-age) and aged (60 wks-of-age) time points. From weaning (3 wks), 
body weight was measured weekly and on the day culled. At 20 or 60-wks-of-age, food was removed between 
7–10 AM and mice were fasted for 5 hrs, with continued access to water. Post-fast, mice were humanely culled by 
carbon dioxide asphyxiation. Body weight and length (nose-to-tail base), and anogenital distance (AGD), were 
measured. Blood was drawn by cardiac puncture and serum separated using Minicollect tubes (Greiner Bio-One 
International, Kremsmünster, Austria). The following organs were rapidly dissected and weighed: in males, the 
whole genitourinary (GU) tract and subsequently dissected testes, vas deferens, epididymis, seminal vesicles 
and prostatic lobes (anterior, dorsolateral and ventral), penis and preputial gland; in females, the left and right 
abdominal mammary glands, whole GU tract and subsequently dissected uterus, ovaries and fallopian tubes; 
and in both males and females, the thymus, heart, lungs, pancreas, liver, spleen, stomach, intestine, colon, kid-
neys, brain and femur; adipose tissue depots (visceral mesenteric, pooled perirenal and retroperitoneal, gonadal 
(epididymal - males and periovariac - females) and interscapular brown); and skeletal muscles (gastrocnemius, 
tibialis, extensor digitorum longus and soleus). Male penis length was also assessed. In the case of paired organs, 
one of the pair was placed into RNAlater (Ambion Inc, Austin, US) and the other in 10% neutral buffered forma-
lin (NBF). Singular organs were halved and placed in RNAlater or 10% NBF. Following incubation (4 °C, ~24 hrs), 
organs in RNAlater were stored at − 80 °C and those fixed in 10% NBF underwent overnight processing and were 
embedded in paraffin wax. Serum aliquots were stored at − 80 °C.
Serum Hormone Measurements. Serum from adult mice was assessed for levels of Insulin-like Growth 
Factor 1 (IGF-1) and Growth Hormone (GH) using the Mouse/Rat IGF-1 Quantikine ELISA (R&D Systems, 
Minneapolis, US) and Millipore Rat Mouse GH ELISA (EMD Millipore, St Charles, US), as specified by the 
manufacturer.
Tissue Pathology, Immunohistochemistry and Immunofluorescence. Formalin-fixed 
paraffin-embedded tissue sections (4 μ m) from adult and aged mice were stained with haematoxylin and eosin 
and assessed for tissue morphology by a pathologist (SJ). For immunohistochemical analyses, adult mouse tissue 
sections were incubated in 0.3% hydrogen peroxide (15 min) and antigen retrieval was performed by decloaker 
(10 mM citrate buffer (pH 6.5); 5 min at 125 °C and 10 sec at 90 °C). Cooled sections were subjected to succes-
sive 30 min blocking incubations in avidin/biotin block (Invitrogen, Mulgrave, Aus); Rodent Block M (Biocare 
Medical, Concord, US); and 5% goat serum. SGTA primary antibody-treated sections were incubated overnight 
(4 °C). SGTA immunoreactivity in normal WT mouse tissues was assessed using ‘full length SGTA’ ProteinTech 
antibody (11019-2-AP rabbit polyclonal; Chicago, US) and in Sgta+/− offspring tissues by ‘N-terminal SGTA’ 
Santa Cruz antibody (sc-373978 mouse monoclonal; Dallas, US). Primary antibody omission was employed as a 
negative control. Immunogenic SGTA was visualised by a standard immunoperoxidase reaction using biotiny-
lated anti-rabbit or anti-mouse antibody (1:400, Dako Aus Pty Ltd, North Sydney, Aus), streptavidin-horseradish 
peroxidase complex (1:500, Dako) and diaminobenzidine tetrahydrochloride. All sections were scanned using the 
NanoZoomer Digital Pathology image scanner (Hamamatsu Photonics, Hamamatsu City, Japan).
For immunofluorescent analyses, tissue sections from adult mice were subjected to blocking as above, except 
10% goat serum was employed, and then incubated overnight (4 °C) in a solution containing SGTA (sc-373978) 
and AR (Santa Cruz, SC-816) primary antibodies. Primary antibody omission served as a negative control. 
Visualisation of immunogenic SGTA and AR were achieved using red Alexa Fluor goat anti-mouse-594 and 
green Alexa Fluor goat anti-rabbit-488 (Invitrogen), respectively. Sections were mounted (Prolong Gold anti-fade 
reagent with DAPI (Invitrogen) blue) and visualised by a Zeiss confocal microscope, ‘Zen’ software and Zeiss 
LDM700 with Lumen X-Cite Series 120PC camera.
Western Blot Analysis. Protein was extracted from homogenised adult mouse brain (~100 mg brain; 350 μ l 
RIPA buffer containing protease inhibitor cocktail (Roche Diagnostics, Indiana, US)) by centrifugation. Protein 
yield was determined by Bradford assay (Bio-Rad Laboratories, Hercules, US; bovine serum albumin (BSA) 
standard). Protein (80 μ g) was subjected to gel electrophoresis utilising Criterion XT 1.0 mm gels (Bio-Rad) and 
transferred to nitrocellulose membrane (Hybond-C Extra 0.45 μ m; Amersham Biosciences, Rydalmere, Aus). 
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Membranes blocked in 3% BSA-TBS/T (Tris buffered saline (TBS)/0.1% Tween-20 (T)) overnight (4 °C) were 
probed for SGTA using ‘full length SGTA’ (ProteinTech), ‘C-terminal SGTA’ (Aviva BioSciences, San Diego, 
US) or ‘N-terminal SGTA’ (Santa Cruz) antibodies diluted at 1:1,000 (full, C-terminal) or 1:500 (N-terminal) in 
1% BSA-TBS/T (60 min, room temperature). Immunoreactivity was detected using polyclonal goat anti-rabbit 
(1:1,000) or rabbit anti-mouse IgG/HRP (1:500) antibodies (Dako) followed by chemiluminescent visualisation 
(Super Signal West Dura Extended Duration, Thermo Fisher Scientific, Scoresby, Aus) and ChemiDoc MP imag-
ing (Bio-Rad). Reference proteins used were actin (Santa Cruz Biotechnology, sc-1616, 1:2,000) or Histone H-3 
(Abcam, ab7766, 1:500).
Quantitative Real Time (qRT-) PCR. Total RNA was extracted from adult brain, ovary, mammary, 
anterior prostate and testis tissue. Tissues were homogenised in Buffer RLT (Qiagen, Germantown, US) and 
2-Mercaptoethanol (Sigma-Aldrich) using a Precellys-24 homogeniser then passed through a QIAshredder col-
umn (Qiagen). Homogenate was then subjected to an RNeasy spin column workflow, as per Qiagen instructions. 
Eluted RNA quality and quantity were assessed (NanoDrop, Thermo Fisher Scientific), following which RNA (1 μ g) 
was DNase treated (Ambion RNA TURBO DNA-free kit) and reverse transcribed (iScript First-Strand cDNA 
Synthesis Kit, Bio-Rad; 500 ng total RNA used as template). qRT-PCR primers for target genes of interest were 
designed using Vector NTI (Life Technologies) and synthesised by Sigma-Aldrich Pty Ltd (Sydney, Aus) (see 
Suppl Table 1). Triplicate qRT-PCR reactions were carried out using iQ SYBR Green Supermix and the CFX384 
real-time PCR detection system (Bio-Rad). In each reaction, 2 μ l cDNA, 0.5 μ l each of FWD and REV primers 
(5 pm/μ l) and 5μ l SYBR Green mastermix (Applied Biosystems) were added to a final volume of 8 μ l. PCR cycling 
conditions were 95 °C for 3 min, followed by 40 cycles of: 95 °C for 15 sec, annealing temperature (as described 
in Suppl Table 1) for 30 sec, and 72 °C for 30 sec; following which steps at 95 °C for 1 min, 55 °C for 1 min and 
60–70 °C for 10 sec (3-step amplification and melt curve) were performed. In parallel, mRNA expression of a 
5 candidate reference gene panel was determined and the 2 most stable (determined by geNorm analysis) were 
used to normalise target gene mRNA expression using the delta-delta cT method. PCR product specificity was 
validated with the use of a melt curve and by GelRed agarose gel electrophoresis. Reference genes utilised for 
normalisation were: ovary and anterior prostate – Actb and Tbp; mammary – Tbp and Hprt1; testis and brain – 
Actb and Tfrc.
Statistical Analyses. All data presented as mean ± SEM of parameters. Shapiro-Wilk tests of normality 
and Levenes statistic tests of homogeneity of variance were performed and Q-Q plots assessed for all parameters. 
One-way ANOVA, with pairwise comparisons (Tukey or Dunnett’s T3 post-hoc), was used to determine the effect 
of genotype (WT, Sgta+/−, Sgta−/−) on mRNA expression. The effect of genotype, age (20, 60 wks) and sex (male, 
female) on body weight were assessed using a linear mixed model. Two-way ANOVA, with pairwise comparisons 
(Sidak or Dunnett’s T3 post-hoc), was used to determine the effect of genotype, age, sex and their interaction on 
the remaining parameters. If tests of normality failed, non-parametric Median tests were employed. Likewise, if 
data did not display homogeneity of variance, post-hoc tests in which equal variances are not assumed (Dunnett’s 
T3) were employed. Observed vs expected frequencies of genotype and sex were assessed by Chi-square analy-
ses using GraphPad Prism ver.6.04 and linear regression analyses to determine relationships between variables 
(Pearson score (R) and P value) were performed using SigmaPlot ver.11; all other aforementioned statistics were 
performed using Statistical Package for Social Scientists ver.20. P < 0.05 was considered statistically significant.
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